Literature DB >> 9059544

Endothelin-1 in the lungs of patients with pulmonary hypertension.

P Cacoub1, R Dorent, P Nataf, A Carayon, M Riquet, E Noe, J C Piette, P Godeau, I Gandjbakhch.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is characterized by an increase in vascular tone and an abnormal proliferation of muscle cells in the walls of pulmonary arteries. Recent studies have found high plasma endothelin-1 (ET-1) concentrations in patients with PH. This study was conducted to assess whether elevated circulating ET-1 levels in PH really reflect excessive local pulmonary production.
METHODS: We prospectively studied ET-1 concentration in lung specimens from 6 control subjects and 13 patients with severe PH referred for lung or heart-lung transplantation (6 patients had primary PH and 7 PH secondary to congenital heart defect). Endothelin-like immunoreactivity (ET-LI) was measured in plasma and lung tissue, using a radioimmunoassay, after ET-1 extraction. Reverse-phase high-performance liquid chromatography was also performed.
RESULTS: Peripheral venous plasma ET-LI concentrations in patients with PH, whatever the cause, were greater than those in controls (10.7 +/- 0.8 vs 5.3 +/- 0.7 pg/ml; P < 0.0005). Pulmonary ET-LI was significantly higher in patients with PH, irrespective of its cause, than in controls (25.2 +/- 5.1 vs 8.1 +/- 1.1 pg/mg, P < 0.03). ET-LI pulmonary concentrations were slightly higher in Eisenmenger than in primary PH, but this was not significant (27.1 +/- 8.6 vs 22.8 +/- 5.4 pg/mg). Linear regression analysis indicated a small but significant correlation between ET-LI pulmonary concentrations and pulmonary vascular resistance in the patients with PH (r = 0.38; P = 0.047). In each case, HPLC separation of ET indicated that most of the immuno-reactivity was detected in the same fraction as ET-1.
CONCLUSIONS: The striking increase in ET-1 pulmonary concentration provides new evidence that excessive local pulmonary ET-1 production may contribute to the vascular abnormalities of pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9059544     DOI: 10.1016/s0008-6363(96)00189-7

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  33 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

2.  The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease.

Authors:  Harry Karmouty-Quintana; Hongyan Zhong; Luis Acero; Tingting Weng; Ernestina Melicoff; James D West; Anna Hemnes; Almut Grenz; Holger K Eltzschig; Timothy S Blackwell; Yang Xia; Richard A Johnston; Dewan Zeng; Luiz Belardinelli; Michael R Blackburn
Journal:  FASEB J       Date:  2012-03-13       Impact factor: 5.191

Review 3.  [Pulmonary arterial hypertension in collagenoses: clinical features, epidemiology, pathogenesis, diagnosis and treatment].

Authors:  K Ahmadi-Simab; W L Gross
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 4.  Pulmonary arterial hypertension: a comparison between children and adults.

Authors:  R J Barst; S I Ertel; M Beghetti; D D Ivy
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

Review 5.  Inhibition of ENaC by endothelin-1.

Authors:  Andrey Sorokin; Alexander Staruschenko
Journal:  Vitam Horm       Date:  2015-03-06       Impact factor: 3.421

Review 6.  The Role of Endothelin in the Pathophysiology of Migraine-a Systematic Review.

Authors:  Afrim Iljazi; Cenk Ayata; Messoud Ashina; Anders Hougaard
Journal:  Curr Pain Headache Rep       Date:  2018-03-19

7.  Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension.

Authors:  Yong Soo Kwon; Su Young Chi; Hong Joon Shin; Eun Young Kim; Byeong Kab Yoon; Hee Jung Ban; In Jae Oh; Kyu Sik Kim; Young Chul Kim; Sung Chul Lim
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

8.  Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice.

Authors:  Metin Aytekin; Adriano R Tonelli; Carol F Farver; Ariel E Feldstein; Raed A Dweik
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

9.  Portopulmonary hypertension in decompensated cirrhosis with refractory ascites.

Authors:  F S Benjaminov; M Prentice; K W Sniderman; S Siu; P Liu; F Wong
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

10.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.